Development Pipeline as at 31 December 2018  ordirected trials New Molecular Entities NMEs and significant indications Regulatory submission dates shown for assets in Phase III and beyond.
As disclosure of compound information is balanced by the business needto maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.
Phase I Compound Mechanism Area Under Investigation Oncology AZD0156 ATM inhibitor solid tumours AZD1390 ATM inhibitor glioblastoma AZD4573 CDK9 inhibitor haematological malignancies AZD4785 KRAS inhibitor solid tumours AZD5153 BRD4 inhibitor solid tumours AZD5991 MCL1 inhibitor haematological malignancies AZD9496 selective oestrogen receptor degrader oestrogen receptor five breast cancer Calquence AZD6738 BTK inhibitor ATR inhibitor haematological malignancies Calquence danvatirsen BTK inhibitor STAT3 inhibitor haematological malignancies Imfinzi adavosertib PD-L1 mAb Wee1 inhibitor solid tumours Imfinzi azacitidine PD-L1 mAb azacitidine myelodysplastic syndrome Imfinzi dabrafenib trametinib PD-L1 mAb BRAF inhibitor MEK inhibitor melanoma Imfinzi Iressa PD-L1 mAb EGFR inhibitor non-small cell lung cancer NSCLC Imfinzi RT platform PD-L1 mAb RT locally-advanced head and neck squamous cell carcinoma, CLOVER NSCLC, small cell lung cancer Imfinzi selumetinib PD-L1 MEK inhibitor solid tumours Imfinzi tremelimumab PD-L1 mAb CTLA-4 mAb solid tumours Imfinzi tremelimumab PD-L1 mAb CTLA-4 mAb chemotherapy 1st line pancreatic ductal adenocarcinoma, oesophageal chemotherapy and small cell lung cancer MEDI2228 BCMA antibody drug conjugate multiple myeloma MEDI3726 PSMA antibody drug conjugate prostate cancer MEDI5083 CD40 ligand fusion protein solid tumours MEDI5752 PD-1 CTLA-4 bispecific mAb solid tumours MEDI7247 ASCT2 antibody drug conjugate haematological malignancies oleclumab CD73 mAb solid tumours oleclumab AZD4635 CD73 mAb A2aR inhibitor EGFRm NSCLC oleclumab Tagrisso CD73 mAb EGFR inhibitor EGFRm NSCLC CVRM AZD9977 MCR CV disease AZD8233  CV disease MEDI6570 LOX-1 mAb CV disease MEDI7219 anti-diabetic type-2 diabetes Respiratory AZD0449 inhaled JAK inhibitor asthma AZD1402 inhaled IL-4Ra asthma AZD5634 inhaled ENaC cystic fibrosis AZD8154 inhaled PI3Kgd asthma MEDI3506 IL-33 mAb chronic obstructive pulmonary disease COPD Other AZD0284 RORg psoriasis respiratory MEDI0700 BAFF B7RP1 bispecific mAb systemic lupus erythematosus MEDI1341 alpha synuclein mAb Parkinson's disease MEDI1814 amyloid beta mAb Alzheimers disease 212 AstraZeneca Annual Report & Form 20-F Information 2018 Additional Information Additional Information Phase II Compound Mechanism Area Under Investigation Oncology adavosertib chemotherapy Wee1 inhibitor chemotherapy ovarian cancer AZD2811 Aurora B inhibitor solid tumours AZD4547 FGFR inhibitor solid tumours AZD4635 A2aR inhibitor solid tumours AZD6738 ATR inhibitor solid tumours AZD8186 PI3K inhibitor solid tumours capivasertib AKT inhibitor breast cancer Imfinzi AZD5069 or PD-L1 mAb CXCR2 antagonist or head and neck squamous cell carcinoma, bladder and NSCLC Imfinzi danvatirsen PD-L1 mAb STAT3 inhibitor Imfinzi Lynparza BAYOU PD-L1 mAb PARP inhibitor 1st line unresectable stage 4 bladder cancer Imfinzi MEDI0457 PD-L1 mAb DNA HPV vaccine head and neck squamous cell carcinoma Imfinzi MEDI0680 PD-L1 mAb PD-1 mAb solid tumours Imfinzi monalizumab PD-L1 mAb NKG2a mAb solid tumours Imfinzi oleclumab PD-L1 mAb CD73 mAb solid tumours Imfinzi tremelimumab PD-L1 mAb CTLA-4 mAb biliary tract, oesophageal Imfinzi tremelimumab PD-L1 mAb CTLA-4 mAb gastric cancer Lynparza adavosertib PARP inhibitor Wee1 inhibitor solid tumours Lynparza AZD6738 PARP inhibitor ATR inhibitor gastric cancer Lynparza AZD6738 or Lynparza PARP inhibitor ATR inhibitor or PARP inhibitor breast cancer adavosertib VIOLETTE Wee1 inhibitor Lynparza Imfinzi PARP inhibitor PD-L1 mAb ovarian cancer, breast cancer, gastric cancer and small cell lung MEDIOLA cancer Tagrisso selumetinib or savolitinib EGFR inhibitor MEK inhibitor or MET inhibitor advanced EGFRm NSCLC TATTON CVRM AZD4831 myeloperoxidase heart failure with a preserved ejection fraction AZD5718 FLAP coronary artery disease AZD8601 VEGF-A CV disease cotadutide MEDI0382 GLP-1 glucagon dual agonist type-2 diabetes obesity MEDI5884 cholesterol modulation CV disease MEDI6012 LCAT CV disease verinurad URAT1 inhibitor chronic kidney disease CKD Respiratory abediterol LABA asthma COPD AZD1419 inhaled TLR9 agonist asthma AZD7594 inhaled SGRM asthma COPD AZD7986 DPP1 COPD AZD8871 MABA COPD AZD9567 oral SGRM rheumatoid arthritis respiratory PT010 LABA LAMA ICS asthma tezepelumab TSLP mAb atopic dermatitis Other anifrolumab Type I IFN receptor mAb lupus nephritis anifrolumab Type I IFN receptor mAb systemic lupus erythematosus subcutaneous MEDI3902 Psl PcrV bispecific mAb prevention of nosocomial Pseudomonas aeruginosa pneumonia MEDI7352 NGF TNF bispecific mAb osteoarthritis pain painful diabetic neuropathy MEDI8852 influenza A mAb influenza A treatment MEDI8897 RSV mAb-YTE passive RSV prophylaxis prezalumab B7RP1 mAb primary Sjgrens syndrome suvratoxumab mAb binding to S. aureus toxin prevention of nosocomial Staphylococcus aureus pneumonia AstraZeneca Annual Report & Form 20-F Information 2018 Development Pipeline 213 Development Pipeline continued Phase III Pivotal Phase II Registration Estimated Filing Compound Mechanism Area Under Investigation US EU Japan China Oncology Calquence BTK inhibitor relapsed refractory mantle cell Launched lymphoma Imfinzi tremelimumab PD-L1 mAb CTLA-4 mAb 1st line NSCLC H2 2019 H2 2019 H2 2019 2020 chemotherapy chemotherapy POSEIDON Imfinzi tremelimumab PD-L1 mAb CTLA-4 mAb Limited disease small cell lung 2020 2020 2020 2020 CRT ADRIATIC CRT cancer Imfinzi tremelimumab PD-L1 mAb CTLA-4 mAb 1st line small cell lung cancer H2 2019 H2 2019 H2 2019 2020 SoC CASPIAN SoC Imfinzi tremelimumab PD-L1 mAb CTLA-4 mAb 1st line urothelial cancer 2020 2020 2020 SoC NILE SoC Imfinzi tremelimumab PD-L1 mAb CTLA-4 mAb 1st line bladder cancer H2 2019 H2 2019 H2 2019 DANUBE Imfinzi tremelimumab PD-L1 mAb CTLA-4 mAb 1st line hepatocellular carcinoma 2020 2020 2020 2020 HIMALAYA Imfinzi tremelimumab PD-L1 mAb CTLA-4 mAb 1st line head and neck squamous H1 2019 H2 2019 H2 2019 KESTREL cell carcinoma Imfinzi tremelimumab PD-L1 mAb CTLA-4 mAb 1st line NSCLC H2 2019 H2 2019 H2 2019 2020 NEPTUNE Lumoxiti PLAIT anti-CD22 recombinant 3rd line hairy cell leukaemia Launched 2020 Orphan Drug, immunotoxin Priority Review Lynparza cediranib PARP inhibitor VEGF recurrent platinum-resistant 2020 CONCERTO inhibitor ovarian cancer savolitinib SAVOIR MET inhibitor papillary renal cell carcinoma 2020 2020 selumetinib SPRINT MEK inhibitor paediatric neurofibromatosis H2 2019 H2 2019 Orphan Drug Orphan Drug type-1 CVRM Epanova omega-3 carboxylic acids severe  Approved Lokelma potassium binder hyperkalaemia Approved Approved H2 2019 2020 roxadustat OLYMPUS, hypoxia-inducible factor anaemia in CKD end-stage H1 2019 Approved ROCKIES prolyl hydroxylase inhibitor renal disease Respiratory Bevespi Aerosphere LABA LAMA COPD Launched Approved Accepted Accepted PT003 Fasenra CALIMA, IL-5R mAb severe, uncontrolled asthma Launched Launched Launched 2020 SIROCCO, ZONDA, BISE, BORA, GREGALE PT010 LABA LAMA ICS COPD 2019 2019 Accepted Accepted PT027 ICS SABA asthma 2020 tezepelumab TSLP mAb severe, uncontrolled asthma 2020 2020 2020 NAVIGATOR, SOURCE Other anifrolumab TULIP Type I IFN receptor mAb systemic lupus erythematosus 2020 2020 2020 Fast Track designation 214 AstraZeneca Annual Report & Form 20-F Information 2018 Additional Information Additional Information Significant Life-cycle Management Estimated Filing Compound Mechanism Area Under Investigation US EU Japan China Oncology Calquence BTK inhibitor 1st line chronic lymphocytic leukaemia 2020 2020 2020 Orphan Drug Orphan Drug Calquence BTK inhibitor relapsed refractory chronic lymphocytic 2020 2020 Orphan Drug Orphan Drug leukaemia Calquence BTK inhibitor relapsed refractory chronic lymphocytic H2 2019 H2 2019 Orphan Drug Orphan Drug leukaemia, high risk Calquence BTK inhibitor haematological malignancies Calquence BTK inhibitor 1st line mantle cell lymphoma 2020 2020 2020 Orphan Drug Imfinzi PD-L1 mAb solid tumours Imfinzi PEARL, China PD-L1 mAb 1st line NSCLC N A N A N A 2020 Imfinzi PACIFIC PD-L1 mAb locally advanced stage 3 NSCLC Approved Approved Approved Accepted Breakthrough designation, Priority Review Imfinzi POTOMAC PD-L1 mAb non-muscle invasive bladder cancer N A 2020 2020 N A Imfinzi CRT PD-L1 mAb CRT locally-advanced stage 3 NSCLC 2020 2020 2020 PACIFIC-2 Imfinzi CRT PD-L1 mAb CRT locally-advanced stage 3 NSCLC N A N A N A 2020 PACIFIC-5, China Imfinzi CTx PD-L1 mAb CTx locally-advanced stage 3 NSCLC 2020 2020 2020 neoadjuvant AEGEAN Imfinzi CTx PD-L1 mAb CTx muscle invasive bladder cancer 2020 2020 2020 NIAGARA Imfinzi VEGF TACE PD-L1 mAb VEGF locoregional hepatocellar carcinoma 2020 2020 2020 2020 EMERALD-1 TACE Lynparza OlympiA PARP inhibitor gBRCA adjuvant breast cancer 2020 2020 2020 Lynparza OlympiAD PARP inhibitor gBRCA metastatic breast cancer Launched Accepted Approved H1 2019 Priority Review Orphan Drug, Priority Review Lynparza POLO PARP inhibitor pancreatic cancer H2 2019 H2 2019 Orphan Drug Lynparza SOLO-3 PARP inhibitor gBRCA PSR ovarian cancer H2 2019 Lynparza abiraterone PARP inhibitor NHA prostate cancer 2020 2020 2020 2020 PROpel Lynparza PROfound PARP inhibitor prostate cancer 2020 2020 2020 2020 Breakthrough designation Lynparza SOLO-1 PARP inhibitor 1st line BRCAm ovarian cancer Approved Accepted Accepted Accepted Priority Review Priority Review Lynparza SOLO-2 PARP inhibitor 2nd line or greater BRCAm PSR ovarian Approved Approved Approved Approved Priority Review Orphan Drug cancer, maintenance monotherapy Tagrisso LAURA EGFR inhibitor stage 3 EGFRm NSCLC 2020 2020 2020 2020 Tagrisso ADAURA EGFR inhibitor adjuvant EGFRm NSCLC 2020 2020 2020 2020 Tagrisso FLAURA EGFR inhibitor 1st line advanced EGFRm NSCLC Approved Approved Approved Accepted Breakthrough designation AstraZeneca Annual Report & Form 20-F Information 2018 Development Pipeline 215 Development Pipeline continued Significant Life-cycle Management continued Estimated Filing Compound Mechanism Area Under Investigation US EU Japan China CVRM Brilinta Brilique P2Y12 receptor antagonist prevention of vaso-occlusive crises in 2020 2020 HESTIA paediatric patients with sickle cell disease Brilinta Brilique P2Y12 receptor antagonist CV outcomes trial in patients with H2 2019 H2 2019 H2 2019 H2 2019 THEMIS coronary artery disease and type-2 diabetes without a previous history of myocardial infarction or stroke Brilinta Brilique P2Y12 receptor antagonist acute ischaemic stroke or transient 2020 2020 2020 THALES ischaemic attack Bydureon GLP-1 receptor agonist type-2 diabetes outcomes study Accepted Approved N A Accepted EXSCEL Bydureon BCise GLP-1 receptor agonist type-2 diabetes Launched Approved autoinjector Epanova omega-3 carboxylic acids CV outcomes study in statin-treated 2020 2020 2020 2020 STRENGTH patients at high CV risk, with persistent  plus low HDL-cholesterol Farxiga Forxiga SGLT-2 inhibitor worsening heart failure or CV death in 2020 2020 2020 2020 Dapa-HF patients with chronic heart failure HFrEF Farxiga Forxiga SGLT-2 inhibitor worsening heart failure or CV death 2020 2020 2020 2020 DELIVER in patients with chronic heart failure HFpEF Farxiga Forxiga SGLT-2 inhibitor renal outcomes and CV mortality 2020 2020 2020 2020 Dapa-CKD in patients with CKD Farxiga Forxiga SGLT-2 inhibitor type-1 diabetes Accepted Accepted Accepted DEPICT Farxiga Forxiga SGLT-2 inhibitor CV outcomes trial in patients with H1 2019 H1 2019 H1 2019 DECLARE type-2diabetes Qtern DPP-4 inhibitor SGLT-2 type-2 diabetes Launched Launched inhibitor FDC roxadustat hypoxia-inducible factor anaemia in myelodysplastic syndrome 2020 2020 prolyl hydroxylase inhibitor saxagliptin dapagliflozin DPP-4 inhibitor SGLT-2 type-2 diabetes Accepted Accepted metformin inhibitor Xigduo XR Xigduo SGLT-2 inhibitor type-2 diabetes Launched Launched 2020 metformin FDC Respiratory Duaklir Genuair LAMA LABA COPD Accepted Launched 2020 Fasenra IL-5R mAb COPD TERRANOVA, GALATHEA Fasenra IL-5R mAb nasal polyposis 2020 2020 OSTRO Symbicort ICS LABA as-needed use in mild asthma N A Accepted N A H2 2019 SYGMA Other Linzess linaclotide GC-C receptor irritable bowel syndrome Approved peptideagonist withconstipation Nexium proton pump inhibitor stress ulcer prophylaxis Accepted 216 AstraZeneca Annual Report & Form 20-F Information 2018 Additional Information
